TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Amortization of Intangible Assets in USD from Q4 2015 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Amortization of Intangible Assets history and growth rate from Q4 2015 to Q4 2024.
  • Teva Pharmaceutical Industries Ltd Amortization of Intangible Assets for the quarter ending December 31, 2024 was $144M, unchanged year-over-year.
  • Teva Pharmaceutical Industries Ltd Amortization of Intangible Assets for the twelve months ending December 31, 2024 was $588M, a 4.55% decline year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2024 was $588M, a 4.55% decline from 2023.
  • Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2023 was $616M, a 15.8% decline from 2022.
  • Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2022 was $732M, a 8.73% decline from 2021.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $144M $0 0% Dec 31, 2024 10-K 2025-02-05
Q3 2024 $146M +$1M +0.69% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $146M -$16M -9.88% Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $152M -$13M -7.88% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $144M -$11M -7.1% Dec 31, 2023 10-K 2025-02-05
Q3 2023 $145M -$20M -12.1% Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $162M -$50M -23.6% Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $165M -$35M -17.5% Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $155M -$33M -17.6% Dec 31, 2022 10-K 2025-02-05
Q3 2022 $165M -$34M -17.1% Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $212M +$39M +22.5% Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $200M -$42M -17.4% Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $188M -$74M -28.2% Dec 31, 2021 10-K 2024-02-12
Q3 2021 $199M -$52M -20.7% Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $173M -$76M -30.5% Jun 30, 2021 10-Q 2022-07-27
Q1 2021 $242M -$16M -6.2% Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $262M -$28M -9.66% Dec 31, 2020 10-K 2023-02-10
Q3 2020 $251M -$4M -1.57% Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $249M -$36M -12.6% Jun 30, 2020 10-Q 2021-07-28
Q1 2020 $258M -$25M -8.83% Mar 31, 2020 10-Q 2021-04-28
Q4 2019 $290M +$33M +12.8% Dec 31, 2019 10-K 2022-02-09
Q3 2019 $255M -$42M -14.1% Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $285M -$17M -5.63% Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $283M -$27M -8.71% Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $257M -$99M -27.8% Dec 31, 2018 10-K 2021-02-10
Q3 2018 $297M -$60M -16.8% Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $302M -$108M -26.3% Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $310M -$11M -3.43% Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $356M -$637M -64.1% Dec 31, 2017 10-K 2020-02-21
Q3 2017 $357M -$454M -56% Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $410M Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $321M Mar 31, 2017 6-K 2017-05-11
Q4 2016 $993M +$155M +18.5% Dec 31, 2016 6-K 2017-11-02
Q3 2016 $811M Sep 30, 2016 6-K 2016-11-15
Q4 2015 $838M Dec 31, 2015 6-K 2016-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.